A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations

Published:2020-03-09 Issue:5 Volume:62 Page:1300-1314
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biometrical Journal

Author:

Jiménez José L.¹²^ORCID,Kim Sungjin³,Tighiouart Mourad³

Affiliation:

1. Biostatistical Sciences and PharmacometricsNovartis Pharma A.G. Basel Switzerland

2. Dipartimento di Scienze MatematichePolitecnico di TorinoTurin Italy

3. Biostatistics and Bioinformatics Research CenterSamuel Oschin Comprehensive Cancer InstituteLos Angeles CA USA

Funder

Foundation for the National Institutes of Health

National Center for Advancing Translational Sciences

H2020 Marie Skłodowska-Curie Actions

National Center for Research Resources

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bimj.201900095

Reference30 articles.

1. Cancer phase I clinical trials: efficient dose escalation with overdose control

2. The bivariate continual reassessment method

3. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials

4. Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical Trials

5. A Parallel Phase I/II Clinical Trial Design for Combination Therapies

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials;Statistics in Biopharmaceutical Research;2024-08-28

2. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials;Biometrical Journal;2023-12-04

3. A Bayesian adaptive design for dual‐agent phase I–II oncology trials integrating efficacy data across stages;Biometrical Journal;2023-05-18

4. Combining Cytotoxic Agents with Continuous Dose Levels in Seamless Phase I-II Clinical Trials;Journal of the Royal Statistical Society Series C: Applied Statistics;2022-10-26

5. A nonparametric Bayesian method for dose finding in drug combinations cancer trials;Statistics in Medicine;2022-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3